艾克鲁斯将女性激素治疗推进到低性欲的第三阶段试验. Acrux advances female testosterone therapy to Phase III trials for low sexual desire.

澳大利亚制药公司Acrux已将女性丸激素治疗推进到低活性的性欲障碍的第三阶段试验. Australian pharmaceutical company Acrux has advanced its female testosterone therapy to Phase III trials for Hypoactive Sexual Desire Disorder. 新的无贴片系统提供了对凝的谨慎替代方案, 显示出积极的试验结果. The new patchless patch system offers a discreet alternative to gels, showing positive trial results. 通过FDA的支持和全球合作伙伴计划,Acrux旨在解决女性健康方面的重大未满足需求. With FDA support and plans for global partnerships, Acrux aims to address a significant unmet need in women's health.